incyte announced disappointing results in a trial to determine whether its blockbuster drug Jakafi can treat a serious coronavirus complication. Incyte is headquartered near Wilmington.
The RUXCOVID study determined that patients 12 years and older suffering from a cytokine storm did not meet its primary endpoint. The condition occurs when the body attacks its own cells, rather than fighting the virus.
Initial data showed no reduction in the proportion of patients receiving ruxolitinib plus standard of care who experienced severe complications including death, respiratory failure requiring mechanical ventilation, or admission to the intensive care unit by Day 29.
A comprehensive analysis including safety data is ongoing. The results of this study do not affect other ongoing non-Covid-19 related ruxolitinib clinical trials or approved uses of ruxolitinib.
“Given the urgent nature of the Covid-19 pandemic and the need for treatments for patients hospitalized with severe Covid-19 associated cytokine storm, the results of the RUXCOVID study are disappointing,” said Steven Stein, M.D., chief medical officer, Incyte. “However, we hope that these findings will contribute to the scientific understanding of this complex disease and to the collective efforts of the biopharma industry to find solutions that improve outcomes for patients with Covid.-19.
Jakafi is used to treat blood conditions. Annual revenues from the drug total more than $1 billion.
